User login
CHICAGO – Dr. Richard Finn presented an update on palbociclib (an oral and selective inhibitor of cyclin-dependent kinases [CDK] 4 and 6) for treating advanced postmenopausal breast cancer at the annual meeting of the American Society of Clinical Oncology.
A phase III trial, with the primary endpoint of progression free survival, is aiming to validate the positive trial results with palbociclib plus letrozole seen in earlier clinical trials. Palbociclib received Breakthrough Therapy designation from the Food and Drug Administration earlier this year.
CHICAGO – Dr. Richard Finn presented an update on palbociclib (an oral and selective inhibitor of cyclin-dependent kinases [CDK] 4 and 6) for treating advanced postmenopausal breast cancer at the annual meeting of the American Society of Clinical Oncology.
A phase III trial, with the primary endpoint of progression free survival, is aiming to validate the positive trial results with palbociclib plus letrozole seen in earlier clinical trials. Palbociclib received Breakthrough Therapy designation from the Food and Drug Administration earlier this year.
CHICAGO – Dr. Richard Finn presented an update on palbociclib (an oral and selective inhibitor of cyclin-dependent kinases [CDK] 4 and 6) for treating advanced postmenopausal breast cancer at the annual meeting of the American Society of Clinical Oncology.
A phase III trial, with the primary endpoint of progression free survival, is aiming to validate the positive trial results with palbociclib plus letrozole seen in earlier clinical trials. Palbociclib received Breakthrough Therapy designation from the Food and Drug Administration earlier this year.
AT THE ASCO ANNUAL MEETING 2013
